MediPal Holdings Management

Management criteria checks 2/4

MediPal Holdings' CEO is Shuichi Watanabe, appointed in Apr 2012, has a tenure of 12.08 years. directly owns 0.082% of the company’s shares, worth ¥430.49M. The average tenure of the management team and the board of directors is 11.7 years and 7.3 years respectively.

Key information

Shuichi Watanabe

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	12.1yrs
CEO ownership	0.08%
Management average tenure	11.7yrs
Board average tenure	7.3yrs

Recent management updates

Recent updates

CEO

Shuichi Watanabe (71 yo)

12.1yrs

Tenure

Mr. Shuichi Watanabe has been Chief Compliance Officer of MediPal Holdings Corporation since June 25, 2020. Mr. Watanabe has been Chief Executive Officer and President at MediPal Holdings Corporation since...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Shuichi Watanabe	Chief Compliance Officer	12.1yrs	no data	0.082% ¥ 430.5m
Yuji Sakon	MD, GM of Administration Division & Director	11.3yrs	no data	no data
Toshihide Yoda	Senior MD of Investor Relations	12.3yrs	no data	0.0057% ¥ 29.8m
Yasuhiro Choufuku	Executive VP & Director	7.9yrs	no data	0.024% ¥ 126.9m
Shinjiro Watanabe	GM of Information Systems Management Division & Director	no data	no data	0.016% ¥ 82.1m

11.7yrs

Average Tenure

69yo

Average Age

Experienced Management: 7459's management team is seasoned and experienced (11.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Shuichi Watanabe	Chief Compliance Officer	24.3yrs	no data	0.082% ¥ 430.5m
Yuji Sakon	MD, GM of Administration Division & Director	12.3yrs	no data	no data
Toshihide Yoda	Senior MD of Investor Relations	14.3yrs	no data	0.0057% ¥ 29.8m
Yasuhiro Choufuku	Executive VP & Director	5.3yrs	no data	0.024% ¥ 126.9m
Shinjiro Watanabe	GM of Information Systems Management Division & Director	11.3yrs	no data	0.016% ¥ 82.1m
Yoko Sanuki	Outside Audit & Supervisory Board Member	no data	no data	no data
Kuniko Shoji	Independent Outside Director	6.3yrs	no data	no data
Toshio Asano	Independent Outside Director	7.3yrs	no data	0.0029% ¥ 14.9m
Hiroshi Iwamoto	Independent Outside Director	3.3yrs	no data	no data
Koichi Mimura	Director	4.3yrs	no data	0.00048% ¥ 2.5m
Mitsuko Kagami	Independent Outside Director	10.3yrs	no data	no data
Seiichi Kasutani	Director	5.3yrs	no data	no data

7.3yrs

Average Tenure

69yo

Average Age

Experienced Board: 7459's board of directors are considered experienced (7.3 years average tenure).

MediPal Holdings Management

Management criteria checks 2/4

Key information

Recent management updates

MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Recent updates

MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion.

Upcoming dividend of JP¥30.00 per share

MediPal Holdings Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Third quarter 2024 earnings released: EPS: JP¥52.80 (vs JP¥59.65 in 3Q 2023)

MediPal Holdings Corporation to Report Q3, 2024 Results on Feb 05, 2024

Second quarter 2024 earnings released: EPS: JP¥28.08 (vs JP¥43.12 in 2Q 2023)

Price target increased by 9.5% to JP¥2,475

Upcoming dividend of JP¥30.00 per share at 2.3% yield

MediPal Holdings Corporation to Report Q2, 2024 Results on Nov 02, 2023

First quarter 2024 earnings released: EPS: JP¥52.32 (vs JP¥39.39 in 1Q 2023)

Price target increased by 12% to JP¥2,198

MediPal Holdings Corporation to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates increase by 14%

MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥23.00 per share at 2.6% yield

Now 22% undervalued

Third quarter 2023 earnings released: EPS: JP¥59.65 (vs JP¥49.09 in 3Q 2022)

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).

MediPal Holdings Corporation to Report Q3, 2023 Results on Feb 01, 2023

Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022)

Upcoming dividend of JP¥23.00 per share

MediPal Holdings Corporation to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings released: EPS: JP¥39.39 (vs JP¥44.98 in 1Q 2022)

MediPal Holdings Corporation to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment deteriorated over the past week

MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Upcoming dividend of JP¥21.00 per share

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 20% undervalued

Second quarter 2022 earnings released: EPS JP¥43.25 (vs JP¥23.93 in 2Q 2021)

Upcoming dividend of JP¥21.00 per share

First quarter 2022 earnings released: EPS JP¥44.98 (vs JP¥32.88 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥114 (vs JP¥176 in FY 2020)

Upcoming dividend of JP¥21.00 per share

MediPal Holdings Corporation to Report Fiscal Year 2021 Results on May 13, 2021

Third quarter 2021 earnings released: EPS JP¥21.05 (vs JP¥52.72 in 3Q 2020)

Revenue and earnings beat expectations

New 90-day high: JP¥2,141

Analysts update estimates

Analysts update estimates

MediPal Holdings Corporation to Report Q3, 2021 Results on Jan 29, 2021

MediPal Holdings Corporation to Report Q2, 2021 Results on Oct 30, 2020

MediPal Holdings Corporation to Report Q1, 2021 Results on Jul 31, 2020

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age